Research output per year
Research output per year
Fingerprint
Dive into the research topics where William Roberts is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
An analysis of Patient Reported Outcomes among Congestive Heart Failure Clinical Trials
Rorah, D., Pollard, J., Walters, C., Roberts, W., Hartwell, M., Hemmerich, C. & Vassar, M., 17 Feb 2023, p. 99.Research output: Contribution to conference › Poster › peer-review
-
Associations of clinical personnel characteristics and controlled substance prescribing practices
Millhollon, R., Elenwo, C., Lundberg, A., Roberts, W., Beaman, J., Bray, N. & Hartwell, M., 1 Sep 2023, In: Journal of Osteopathic Medicine. 123, 9, p. 451-458 8 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Equity Reporting in Systematic Reviews of Opioid Treatment of Chronic Non-Cancer Pain with Patient-Reported Outcomes
Landers, E., Batioja, K., Nguyen, T., Hester, M., Pasha, J., Roberts, W. & Hartwell, M., 2023, In: Journal of Pain and Palliative Care Pharmacotherapy. 37, 1, p. 52-62 11 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
An analysis of harms reporting in systematic reviews regarding ketorolac for management of perioperative pain
Modi, J., Magee, T., Rucker, B., Flores, H., Wise, A., Kee, M., Garrett, M., Roberts, W. & Vassar, M., Nov 2022, In: British Journal of Anaesthesia. 129, 5, p. 767-775 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Associations of Clinical Personnel Characteristics and Controlled Substance Prescribing Practices
Millhollon, R., Elenwo, C., Lundberg, A., Roberts, W., Beaman, J., Bray, N. & Hartwell, M., 10 Sep 2022.Research output: Contribution to conference › Poster › peer-review
Press/Media
-
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
15/02/21
2 items of Media coverage
Press/Media
-
FDA Approves G1 Therapeutics’ COSELA (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
14/02/21
1 item of Media coverage
Press/Media
-
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
12/02/21 → 13/02/21
29 items of Media coverage
Press/Media